By expanding coverage for these evidence-based obesity treatments, employers can significantly improve long-term health outcomes for employees while effectively lowering costs associated with chronic diseases, disabilities, and lost productivity, while supporting employee morale and mental well-being
Approval of additional GLP-1 agonists has reduced injection burden to weekly and recently an oral GLP-1 product was approved
Diet and lifestyle changessuch as smaller meals, avoiding sulfur-rich and carbonated foods, chewing slowly, and staying hydratedcan significantly reduce the frequency and severity of Ozempic-related burps and bloating
Immunological imbalances associated with epileptic seizures in type 2 diabetes mellitus
Without a preservative, any bacteria introduced will happily multiply, quickly rendering your solution unsafe